MedTrace Logo

Phenylbutyrate in Proteinuric Nephropathies

NCT02343094 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2 urinary expression in proteinuric patients.

Conditions

  • Proteinuric Diseases

Interventions

DRUG

PBA 7,5g/d

Treatment for 14 days with PBA

DRUG

PBA 15g/d

Treatment for 14 days with PBA

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Bertrand KNEBELMANN · Service de Néphrologie Adulte, Hôpital Necker

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-12-31
Completion
2016-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02343094 on ClinicalTrials.gov